Clinical Trials on Stage IIIB Uterine Corpus Cancer AJCC v7 in Netherlands

Total 24 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Uterine Corpus Leiomyosarcoma | Stage I Uterine Sarcoma AJCC v7

United States, Belgium, France, Spain, United Kingdom, Netherlands, Norway, Venezuela
Radboud University Medical Center
Maastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaborators

Recruiting

PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer (PROMOTE)

Endometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IV

Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Chordoma | Rhabdomyosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Untreated Childhood Rhabdomyosarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 and other conditions

United States, Netherlands, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Academisch Medisch Centrum - Universiteit van Amsterdam...
UMC Utrecht

Completed

PDL-1 Targeting in Resectable Oesophageal Cancer (PERFECT)

Esophageal Cancer, Stage II | Esophageal Cancer Stage III

Netherlands
Leiden University Medical Center
Comprehensive Cancer Centre The Netherlands; Dutch Cancer Society

Active, not recruiting

PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer (PORTEC-4a)

Endometrial Cancer Stage I | Endometrial Cancer Stage II

Netherlands, Germany, Belgium, France, Austria, Czechia, Ireland, Switzerland
University Hospital, Essen

Recruiting

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)

NSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIA

Belgium, Germany, Netherlands
The Netherlands Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib and Radiotherapy in Head and Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage III

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)

Stage I-III Small Cell Lung Cancer

Netherlands
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
UMC Utrecht

Unknown

MRI Optimization Study in Stage III NSCLC

Stage III Non-small Cell Lung Cancer

Netherlands
Radboud University Medical Center

Terminated

Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy (IDEAL-VMAT)

Stage III Non-small Cell Lung Cancer | Individualized Radiation Dose Escalation

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)

Stage I-III Non-small Cell Lung Cancer

Netherlands
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
Leiden University Medical Center
Jessa Hospital; The Netherlands Cancer Institute

Recruiting

Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy (Prediction)

Immunotherapy | Non Small Cell Lung Cancer Stage III

Netherlands, Belgium
Maastricht Radiation Oncology
University Medical Center Groningen; The Netherlands Cancer Institute

Completed

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)

Non Small Cell Lung Cancer (NSCLC) | Stage III Non-Small Cell Lung Cancer | Radical Treatment

Netherlands
Radboud University Medical Center
UMC Utrecht; Amsterdam UMC, location VUmc; St. Antonius Hospital; Dijklander Ziekenhuis and other collaborators

Recruiting

The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients (NVALT31-PET)

Stage III Non-small Cell Lung Cancer

Netherlands
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
The Netherlands Cancer Institute

Recruiting

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer (CisCon)

Fallopian Tube Carcinoma | Peritoneal Cancer | FIGO Stage III Ovarian Cancer

Netherlands
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
ETOP IBCSG Partners Foundation
Bristol-Myers Squibb; Frontier Science Foundation, Hellas

Completed

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS)

Non-small Cell Lung Cancer Stage III

Switzerland, Netherlands, Spain, Belgium, Germany
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain

Clinical Trials on Stage IIIB Uterine Corpus Cancer AJCC v7 in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations